CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,921.50 | 15.50 | -0.17% |
| CAC 40 | 7,840.86 | 7.98 | 0.10% |
| DAX 40 | 25,362.05 | 84.37 | 0.33% |
| Dow JONES (US) | 52,053.25 | 202.70 | 0.39% |
| FTSE 100 | 10,686.83 | 30.55 | 0.29% |
| HKSE | 24,345.22 | 74.02 | 0.30% |
| NASDAQ | 27,238.63 | 7.27 | -0.03% |
| Nikkei 225 | 67,777.52 | 1,253.40 | -1.82% |
| NZX 50 Index | 13,749.60 | 78.02 | -0.56% |
| S&P 500 | 7,811.75 | 4.51 | 0.06% |
| S&P/ASX 200 | 8,783.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,800.86 | 3.62 | 0.10% |